Answers are grounded in this paper and cite their sources.
Develops elastin-like peptide nanoparticles that neutralize SARS-CoV-2, suggesting a new antiviral approach.
Elastin-like polypeptides (ELPs) are self-assembling recombinant biopolymers that can be precisely engineered to display functional targeting ligands. In this study, we developed ELP-based nanoparticles (NPs) displaying the variable domain of the heavy chain of heavy-chain-only antibodies (VHHs) targeting the SARS-CoV-2 spike protein. By tuning VHH selection, multivalency, and surface display density, we created targeted ELP NPs capable of blocking entry of spike-protein-presenting virus-like particles (VLPs) and live viruses, with subnanomolar IC₅₀ values, significantly outperforming the monovalent VHH equivalents. Notably, optimizing multivalency and VHH density unlocked broad virus-neutralizing potency against multiple variants, including Omicron variants resistant against the monovalent VHH equivalents. Confocal imaging further revealed that VHH-ELP NPs formed aggregates with VLPs, enhancing uptake by M1 macrophages, suggesting potential for eliciting vaccinal effects. Overall, this work highlights the versatility of ELP NPs as a tunable antiviral platform and provides design principles for next-generation nanotherapeutics against evolving viral threats.
No takes yet. Share an insight, caveat, or question.
Le et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: